The corporate venture fund is a sector-exclusive life sciences venture and growth equity fund focused on Asia, particularly China. Originally established in 2008 as a corporate venture subsidiary of a Big Pharma, the firm has since spun off and operates as an independent investment firm with offices in China and the US. The fund currently has ~$4.5B AUM and is investing from their fifth fund, a $750M fund that was closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. With both USD and RMB funds, the firm focuses on China but also considers opportunities from USA.
In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.
The firm is seeking experienced management teams that are going rapidly and emerging as market leaders. The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment